Most retail traders lose not because they can't read a chart — but because they're flying blind on the information that actually moves small-cap stocks: dilution events, FDA decisions, government contract awards, and supply-chain shifts. This guide covers the tools that professional event-driven traders use to stay ahead of those catalysts.
Generic stock screeners and financial data aggregators give you lagging price and volume data that millions of other traders already have. The tools that create an actual edge are the ones that surface event-driven intelligence before it's priced in — regulatory filings the moment they hit, catalyst calendars days before events, supply chain relationships that explain why a stock is moving before the news hits broader media.
The best research stacks for active traders in 2026 focus on these five categories:
The most comprehensive dilution risk intelligence platform for small and micro-cap stocks. Tracks shelf registrations (S-3 and S-1), at-the-market offering agreements, 424B prospectus supplements, outstanding warrants, convertible note structures, and PIPE agreements across 7,300+ tickers. Each company receives a proprietary dilution severity score updated in real time as new filings are accepted. Alerts fire the day an offering-related document hits — not the next morning, and not after the stock has already moved.
Best for: traders holding or considering small-cap stocks where dilution is the primary downside risk. Essential before entering any position in a company with an active shelf registration, convertible debt, or high warrant overhang.
Visit DilutionWatch →FDA catalyst intelligence for biotech and biopharma event-driven trading. Aggregates PDUFA dates from verified regulatory filings, AdCom meeting schedules, Phase 2/3 clinical trial data timelines, NDA/BLA submission tracking, and cash runway estimates derived from quarterly balance sheets. Covers 950+ small and mid-cap biotech companies with active development pipelines. The catalyst calendar updates automatically as new FDA action dates are published — no manual research required.
Best for: traders who play binary biotech events, PDUFA dates, and Phase 2/3 data readouts. Also valuable for identifying cash-stressed biotechs approaching catalyst windows where dilution risk is elevated.
Visit BiotechSigns →Maps corporate supply chain relationships and customer concentration exposures disclosed in regulatory filings and material agreement exhibits. Identifies which small-cap stocks are exposed to large-cap earnings events through hidden supplier relationships — a supplier that generates 30% of its revenue from a single customer will move when that customer beats or misses earnings, often before that connection is widely understood by retail traders. Tracks contract award disclosures, customer concentration changes, and material agreement modifications.
Best for: traders looking to front-run supply chain events and identify which small caps benefit or suffer when a major customer reports earnings, announces capacity expansion, or discloses a vendor change.
Visit ChainSifter →Government procurement intelligence for publicly traded defense, services, and technology companies. Tracks federal contract awards, IDIQ ceiling expansions, task order activity, and option exercised notices filed through public procurement databases. Government contract signals often precede official revenue guidance by weeks or months — the award is public long before management updates its outlook. Available exclusively to TraderTools Pro Founding Members at launch.
Event-driven traders rarely operate in a single category. A biotech company with an upcoming PDUFA date may also have an active shelf registration and a key government contract. Seeing all three signals simultaneously — catalyst timing, dilution risk, and contract exposure — gives you a complete picture that traders relying on a single tool never have.
The other issue is workflow friction. Switching between multiple platforms, each with its own login, alert system, and data format, creates cognitive overhead that slows down decision-making exactly when speed matters most. A unified bundle eliminates that friction and surfaces cross-signal correlations that siloed tools can't catch.
For example: a biotech company with a PDUFA date in 45 days, an active ATM offering agreement, and a government contract for a related diagnostic product tells a very different story than the chart alone. DilutionWatch flags the ATM risk. BiotechSigns shows the PDUFA timeline. ChainSifter surfaces the contract exposure. Together, they tell you whether this is a position to size up or stay away from.
The most important factor in event-driven research is how quickly a platform captures new filings. Regulatory filings are public the moment they are accepted. Tools that process filings in real time versus batching them overnight create dramatically different signal quality. Ask specifically: how quickly does the tool alert on a new prospectus supplement (424B)? That filing is often the first public disclosure of a stock offering.
Generic "new filing" alerts are noise. A platform that tells you a company filed something is less useful than one that tells you the company filed a 424B5 — meaning it is actively drawing on a shelf registration and selling shares into the market right now. Alert specificity determines whether you engage with every notification or start ignoring the system entirely.
Raw filing data requires analysis. The best tools apply proprietary scoring models that synthesize multiple signals into a single risk or opportunity indicator — DilutionWatch's severity score aggregates shelf size, draw history, warrant count, and cash position into one number. That saves hours of manual research per position and allows traders to manage larger watchlists effectively.
Coverage across 7,300+ tickers versus a few hundred determines whether the tool is useful for discovery or just monitoring names you already know. Comprehensive coverage means you can screen for new opportunities — not just watch ones you've already identified.
See also: small-cap trading tools, SEC filing research, and event-driven trading tools.
Standard screeners filter on price, volume, and technical indicators — lagging signals that millions of traders already see. TraderTools Pro focuses on event-driven intelligence derived from regulatory filings: dilution events, FDA catalysts, supply chain relationships, and government contract awards. These signals arrive before they are widely priced into the stock.
DilutionWatch monitors regulatory filing feeds in real time. When a prospectus supplement (424B filing) indicating active share sales is accepted, the alert fires within minutes — not overnight. For ATM offering agreements disclosed in 8-K filings, the alert fires the same day the filing is accepted.
Yes. BiotechSigns tracks the full regulatory lifecycle — from IND filing through NDA submission through PDUFA decision — which is useful for both short-term event trades and longer-term pipeline investors. The cash runway estimator helps longer-term holders understand dilution risk over multi-quarter holding periods.
TraderTools Pro focuses on fundamental event intelligence from regulatory filings rather than order flow data. For options-focused traders, the biotech catalyst calendar is particularly useful because it identifies the binary events that drive unusual options activity before that activity appears in the tape.
The Founding Member rate is $99/month for full access to all active tools in the TraderTools Pro bundle. This rate is locked for the lifetime of the subscription as long as it remains active. New tools added to the bundle — including Contract Trader — are included at no additional cost to Founding Members.